Answers are grounded in this paper and cite their sources.
Non-small cell lung cancer (NSCLC) is among the most common and lethal malignancies globally. The third-generation epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor osimertinib has become a first-line therapeutic option for patients harboring EGFR mutations. However, acquired resistance to osimertinib inevitably emerges during treatment, but the underlying molecular mechanisms have not been fully elucidated, resulting in few effective salvage strategies. Increasing evidence suggests that epigenetic dysregulation, particularly aberrant DNA methylation, plays a critical role in therapeutic failure. However, whether decitabine, a DNA demethylating agent, can resensitize osimertinib-resistant NSCLC cells to osimertinib, as well as the link between DNA methylation and autophagy in this process, remains largely uninvestigated. We generated two isogenic osimertinib-resistant NSCLC models, namely PC-9OR and H1975OR, via continuous exposure of the parental PC-9 and H1975 cell lines, respectively. We used immunohistochemistry and the Illumina Infinium MethylationEPIC BeadChip (850K methylation array) to assess TP53INP1 expression and promoter methylation status in tumor tissues and resistant cells. A suite of in vitro functional assays and in vivo xenograft experiments were performed to define the biological role of TP53INP1 in osimertinib-resistant NSCLC. To map the downstream signaling networks regulated by TP53INP1 , we utilized RNA sequencing, immunofluorescence imaging, and co-immunoprecipitation. Decitabine increased responsiveness to osimertinib in resistant NSCLC cells and xenograft tumors. Combined treatment suppressed proliferation and increased apoptosis relative to either agent alone. Joint analysis of methylation and transcriptome profiles highlighted TP53INP1 as a potential mediator. In resistant cells, low TP53INP1 expression coincided with promoter hypermethylation. Decitabine reduced this methylation and restored TP53INP1 expression, together with increased LC3-II and reduced p62/SQSTM1. These changes were consistent with enhanced autophagic activity. TP53INP1 was also detected in LC3-containing complexes, indicating an association with the autophagy machinery without establishing direct regulation of autophagosome formation. Inhibition of autophagy partially weakened decitabine-dependent resensitization to osimertinib. Collectively, the data are compatible with a model in which TP53INP1 re-expression and autophagy contribute to resensitization, although additional mechanisms may also be involved. Our findings show that decitabine treatment was associated with reduced TP53INP1 promoter methylation and increased TP53INP1 expression in osimertinib-resistant NSCLC cells. TP53INP1 expression was accompanied by changes in autophagy-related markers and increased sensitivity to osimertinib. Together, these findings suggest that TP53INP1-associated autophagy may contribute to decitabine-induced osimertinib resensitization, providing a basis for further investigation of this pathway in osimertinib-resistant NSCLC.
No takes yet. Share an insight, caveat, or question.
Dou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: